Addition of Cisplatin to Irinotecan Not Effective for Second-Line Gastric Cancer

Share this content:
No survival benefit was observed upon adding cisplatin to irinotecan after S-1 monotherapy failure in patients with advanced gastric cancer.
No survival benefit was observed upon adding cisplatin to irinotecan after S-1 monotherapy failure in patients with advanced gastric cancer.

No survival benefit was observed upon adding cisplatin to irinotecan after S-1 monotherapy failure in patients with advanced gastric cancer, a recent study published online in the European Journal of Cancer has shown.

Because the optimal second-line regimen for treating advanced gastric cancer remains unclear, researchers sought to examine the survival benefit of cisplatin plus irinotecan compared with irinotecan monotherapy in patients initially treated with S-1, an oral fluoropyrimidine, monotherapy.

Researchers enrolled 68 patients with advanced gastric cancer and 95  with recurrent gastric cancer. Patients were randomly assigned to receive cisplatin 30mg/m2 plus irinotecan 60mg/m2 every 2 weeks or irinotecan 150mg/m2 every 2 weeks alone.

Results showed that the median overall survival was 13.9 months (95% CI: 10.8-17.6) for the combination group versus 12.7 months (95% CI: 10.3-17.2) for the irinotecan group (HR = 0.834; 95% CI: 0.596-1.167; P = 0.288).

Researchers found no significant differences in progression-free survival or response rate between both groups.

RELATED: MK-2206 Not Effective in Gastric, Gastroesophageal Junction Cancers

An exploratory subgroup analysis, however, showed that cisplatin plus irinotecan was significantly more effective for those with intestinal-type advanced gastric cancer compared with irinotecan monotherapy (OS: 15.8 vs 14.0 months;P = 0.019).

In regard to safety, the combination group had a higher incidence of grade 3-4 anemia and elevated serum lactate dehydrogenase levels compared with irinotecan alone.

Reference

  1. Nishikawa K, Fujitani K, Inagaki H, et al. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer. 2015. [Epub ahead of print]. doi: 10.1016/j.ejca.2015.02.009.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters